Patents by Inventor Mirella Ezban Rasmussen

Mirella Ezban Rasmussen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Factor VIII:C nucleic acid molecules
    Patent number: 7138505
    Abstract: Methods and compositions are provided for recombinant DNA production of Factor VIIIC and truncated derivatives thereof. Based on amino acid sequences, probes are developed for isolating messenger RNA, cDNA and/or chromosomal DNA encoding for Factor VIIIC. The Factor VIIIC gene in its entirety, a fragment thereof, or a cDNA is then used for expression of Factor VIIIC in a host. The bacteriophage ?FVIII23D containing the 14.43 kb EcoRI fragment was deposited at the A.T.C.C. on Jan. 4, 1984 and given Accession No. 40094. Also, the vector pSVF8-200 was deposited at the A.T.C.C. on Jul. 17, 1985 and given Accession No. 40190.
    Type: Grant
    Filed: August 13, 1990
    Date of Patent: November 21, 2006
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: George Kuo, Frank Masiarz, Martha Truett, Pablo Valenzuela, Mirella Ezban Rasmussen, Daniel Caput, Rae Lyn Burke, Carol Pachl
  • Protein complexes having factor VIII:C activity and production thereof
    Publication number: 20040137579
    Abstract: Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an &agr;1-antitrypsin signal sequence.
    Type: Application
    Filed: December 1, 2003
    Publication date: July 15, 2004
    Applicants: Chiron Corporation, Novo Nordisk A/S
    Inventors: Barbara Chapman, Rae Lyn Burke, Mirella Ezban Rasmussen, Jan Mollar Mikkelson
  • Protein complexes having factor VIII:C activity and production thereof
    Publication number: 20030170825
    Abstract: Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an &agr;1-antitrypsin signal sequence.
    Type: Application
    Filed: September 26, 2002
    Publication date: September 11, 2003
    Applicant: Chiron Corporation
    Inventors: Barbara Chapman, Rae Lyn Burke, Mirella Ezban Rasmussen, Jan Moller Mikkelson
  • Protein complexes having factor VIII:C activity and production thereof
    Publication number: 20010016340
    Abstract: Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an &agr;1-antitrypsin signal sequence.
    Type: Application
    Filed: December 22, 2000
    Publication date: August 23, 2001
    Applicant: Chiron Corporation and Novo Nordisk A/S
    Inventors: Barbara Chapman, Rae Lyn Burke, Mirella Ezban Rasmussen, Jan Moller Mikkelson
  • Protein complexes having factor VIII:C activity and production thereof
    Patent number: 6228620
    Abstract: Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an &agr;1-antitrypsin signal sequence.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: May 8, 2001
    Assignees: Chiron Corporation, Novo Nordisk A/S
    Inventors: Barbara Chapman, Rae Lyn Burke, Mirella Ezban Rasmussen, Jan Moller Mikkelson
  • Protein complexes having Factor VIII:C activity and production thereof
    Patent number: 6060447
    Abstract: Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an .alpha..sub.1 -antitrypsin signal sequence.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: May 9, 2000
    Assignees: Chiron Corporation, Novo Nordisk A/S
    Inventors: Barbara Chapman, Rae Lyn Burke, Mirella Ezban Rasmussen, Jan Moller Mikkelson
  • Protein complexes having factor VIII:C activity and production thereof
    Patent number: 5789203
    Abstract: Recombinant protein complexes having human Factor VIII:C activity are expressed in a eukaryotic host cell by transforming the host cell with first and second expression cassettes encoding a first polypeptide substantially homologous to human Factor VIII:C A domain and a second polypeptide substantially homologous to human Factor VIII:C C domain, respectively. In the present invention, the first polypeptide may be extended having at its C-terminal a human Factor VIII:C B domain N-terminal peptide, a polypeptide spacer of 3-40 amino acids, and a human Factor VIII:C B domain C-terminal peptide. Expression of the second polypeptide is improved by employing an .alpha..sub.1 -antitrypsin signal sequence.
    Type: Grant
    Filed: June 27, 1994
    Date of Patent: August 4, 1998
    Assignees: Chiron Corporation, Novo Nordisk A/S
    Inventors: Barbara Chapman, Rae Lyn Burke, Mirella Ezban Rasmussen, Jan Moller Mikkelson
  • Method and composition for preparation of factor VIIIC
    Patent number: 5783671
    Abstract: Methods and compositions are provided for recombinant DNA production of Factor VIIIC and truncated derivatives thereof. Based on amino acid sequences, probes are developed for isolating messenger RNA and/or chromosomal DNA encoding for Factor VIIIC. The Factor VIIIC gene in its entirety or encoding for a fragment thereof is then used for expression of Factor VIIIC in a host. The bacteriophage .lambda.FVIII23D containing the 14.43 kb EcoRI fragment was deposited at the A.T.C.C. on Jan. 4, 1984 and given Accession No. 40094.
    Type: Grant
    Filed: October 26, 1993
    Date of Patent: July 21, 1998
    Assignees: Chiron Corporation, Novo Nordisk A/S
    Inventors: George Kuo, Frank Masiarz, Martha Truett, Pablo Valenzuela, Mirella Ezban Rasmussen, Jennifer M. Favaloro